Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways

Current Opinion in Urology

Volumn 18, Issue 5, 2008, Pages 524-532

  Wallerand, Hervé ^a   Reiter, Robert R ^b   Ravaud, Alain ^c  

^a HÔPITAL PELLEGRIN   (France)

^b HÔPITAL SAINT ANDRÉ   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bladder cancer; Molecular pathways; Targeted therapy

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; 4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 7 HYDROXYSTAUROSPORINE; BATIMASTAT; BB 251; BEVACIZUMAB; BORTEZOMIB; CANERTINIB; CEDIRANIB; CETUXIMAB; CGS 27023A; DEFOROLIMUS; ENDOSTATIN; ERLOTINIB; EVEROLIMUS; FLAVOPIRIDOL; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GW 52216; GW 57016; LONAFARNIB; MATUZUMAB; MDX 447; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; OBLIMERSEN; OMNITANG; ONYX 015; PANITUMUMAB; PD 328901; PELITINIB; PERTUZUMAB; PRINOMASTAT; R 11577; R ROSCOVITINE; REBIMASTAT; ROSCOVITINE; SORAFENIB; STAUROSPORINE; SUNITINIB; SUO 11248; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN P53;

ADVANCED CANCER; BLADDER CANCER; BLADDER METASTASIS; CARCINOGENESIS; DISEASE COURSE; DRUG MECHANISM; GENE MUTATION; HUMAN; PATHOGENESIS; PHARMACOGENOMICS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; BLADDER TUMOR; CELL CYCLE; DNA METHYLATION; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENE THERAPY; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); TUMOR SUPPRESSOR GENE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; CELL CYCLE; DNA METHYLATION; DRUG DELIVERY SYSTEMS; GENE THERAPY; GENES, RETINOBLASTOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 54549092123     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e3283097889     Document Type: Review

References (76)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Cancer Base No.5. Lyon: IARC Press; 2001.
2. Bartsch H, Petruzzelli S, De Flora S, et al. Carcinogen metabolism in human lung tissues and the effect of tobacco smoking: results from a case-control multicenter study on lung cancer patients. Environ Health Perspect 1992; 98:119-124.
3. Dimopoulos MA, Moulopoulos LA. Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder. J Clin Oncol 1998; 16:1601-1612.
4. Cote RJ, Esrig D, Groshen S, et al. p53 and treatment of bladder cancer. Nature 1997; 385:123-125.
5. Knowles MA. What we could do now: molecular pathology of bladder cancer. Mol Pathol 2001; 54:215-221.
6. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994; 69:1120-1125.
7. Neal DE, Sharples L, Smith K, et al. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990; 65:1619-1625.
8. Izawa JI, Slaton JW, Kedar D, et al. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep 2001; 8:9-15.
9. Jimenez RE, Hussain M, Bianco FJ Jr, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001; 7:2440-2447.
10. Nicholson RI, Gee JM, Harper ME. EGFRand cancer prognosis. Eur J Cancer 2001; 37 (Suppl 4):S9-S15.
11. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20 (18 Suppl):1S-13S.
12. Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the antiepidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000; 6:4874-4884.
13. Nutt JE, Lazarowicz HP, Mellon JK, Lunec J. Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. Br J Cancer 2004; 90:1679-1685.
14. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of antiepidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000; 6:3739-3747.
15. Philips G, Sanford B, Halabi S, et al. Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): analysis of the second cohort of CALGB 90102. J Clin Oncol 2006; 24:236S. (suppl; abstr 4578).
16. Meyerhardt JA, Zhu AX, Enzinger PC, et al. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol 2006; 24:1892-1897.
17. Perrotte P, MatsumotoT, Inoue K, et al. Antiepidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1 999; 5:257-265.
18. Bellmunt J, de Wit R, Albiol S, et al. New drugs and new approaches in metastatic bladder cancer. Crit Rev Oncol Hematol 2003; 47:195-206.
19. Hussain M, Smith DC, Vaishampayan U, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007; 25:2218-2224.
20. Underwood M, Bartlett J, Reeves J, et al. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res 1995; 55:2422-2430.
21. Orlando C, Sestini R, Vona G, et al. Detection of c-erbB-2 amplification in transitional cell bladder carcinoma using competitive PCR technique. J Urol 1996; 156:2089-2093.
22. Latif Z, Watters AD, Dunn I, et al. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 2004; 40:56-63.
23. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar((R))), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2005; 407:597-612.
24. ClinicalTrials.gov: Information on clinical trials and human research studies. http://www.clinicaltrials.gov. [Updated on July 2006]
25. Dalbagni G, Presti J, Reuter V, et al. Genetic alterations in bladder cancer. Lancet 1993; 342:469-471.
26. Dinney CP, McConkey DJ, Millikan RE, et al. Focus on bladder cancer. Cancer Cell 2004; 6:111-116.
27. Buyru N,Tigli H,Ozcan F, Dalay N. Ras oncogene mutations in urine sediments of patients with bladder cancer. Biochem Mol Biol 2003; 36:399-402.
28. Herrera R, Sebolt-Leopold JS. Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. Trends Mol Med 2002; 8 (4 Suppl):S27-S31.
29. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3:11-22.
30. Pagliaro LC. Gene therapy for bladder cancer. World J Urol 2000; 18:148-151.
31. Kuball J, Wen SF, Leissner J, et al. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol 2002; 20:957-965.
32. Pagliaro LC, Keyhani A, Williams D, et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol 2003; 21:2247-2253.
33. Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B geneattenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3:639-645.
34. Pagliaro LC, Keyhani A, Liu B, et al. Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. Urol Oncol 2003; 21:456-462.
35. Khuri FR, Nemunaitis J, Ganly I, et al. a controlled trial of intratumoral ONYX015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6:879-885.
36. Gomella LG, Mastrangelo MJ, McCue PA, et al. Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol 2001; 166:1291-1295.
37. Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 1999; 286:2507-2510.
38. Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8:282-288.
39. Bykov VJ, Zache N, Stridh H, et al. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 2005; 24:3484-3491.
40. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996; 381:713-716.
41. Xu HJ, Xu K, Zhou Y, et al. Enhanced tumor cell growth suppression by an N-terminal truncated retinoblastoma protein. Proc Natl Acad Sci U S A 1994; 91:9837-9841.
42. Schnier JB, Nishi K, Goodrich DW, Bradbury EM. G1 arrest and downregulation of cyclin E/cyclin-dependent kinase 2 by the protein kinase inhibitor staurosporine are dependent on the retinoblastoma protein in the bladder carcinoma cell line 5637. Proc Natl Acad Sci U S A 1996; 93:5941-5946.
43. Senderowicz AM. Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol Ther 2003; 2 (4 Suppl 1):S84-S95.
44. Cooke PW, James ND, Ganesan R, et al. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. BJU Int 2000; 85:829-835.
45. Hussain SA, Ganesan R, Hiller L, et al. BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder. Oncol Rep 2003; 10:571-576.
46. Schaaf A, Sagi S, Langbein S, et al. Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides. Urol Oncol 2004; 22:188-192.
47. Kikuchi E, Menendez S, Ohori M, et al. Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin. Clin Cancer Res 2004; 10:1835-1842.
48. Inoue K, Chikazawa M, Fukata S, et al. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder. Clin Cancer Res 2002; 8:2389-2398.
49. Muramaki M, Miyake H, Hara I, et al. Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in ahuman bladder cancer KoTCC-1 model. J Urol 2004; 172 (4 Pt 1):1485-1489.
50. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3:24-40.
51. Kim ES, Serur A, Huang J, et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A 2002; 99:11399-11404.
52. Inoue K, Perrotte P, Wood CG, et al. Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. Clin Cancer Res 2000; 6:4422-4431.
53. Cote RJ, Laird PW, Datar RH. Promoter hypermethylation: a new therapeutic target emerges in urothelial cancer. J Clin Oncol 2005; 23:2879-2881.
54. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006; 5:37-50.
55. Cheng JC, Matsen CB, Gonzales FA, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 2003; 95:399-409.
56. Holleran JL, Parise RA, Joseph E, et al. Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res 2005; 11:3862-3868.
57. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/ Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29-39.
58. Krystal GW, Sulanke G, Litz J, et al. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 2002; 1:913-922.
59. Goel A, Arnold CN, Niedzwiecki D, et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 2004; 64:3014-3021.
60. Lonardo F, Dragnev KH, Freemantle SJ, et al. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res 2002; 8:54-60.
61. Määttä M, Santala M, Soini Y, et al. Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors. Tumour Biol 2004; 25:188-192.
62. Xie M, Sun Y, Li Y. Expression of matrix metalloproteinases in supraglottic carcinoma and its clinical implication for estimating lymph node metastases. Laryngoscope 2004; 114:2243-2248.
63. Pellikainen JM, Ropponen KM, Kataja VV, et al. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004; 10:7621-7628.
64. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18:1135-1149.
65. Zeng ZS, Cohen AM, Guillem JG. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogen-esis 1999; 20:749-755.
66. Crawford RA, Caldwell C, Iles RK, et al. Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer. Br J Cancer 1998; 78:210-214.
67. Sreedhar AS, Soti C, Csermely P. Inhibition of Hsp90: a new strategy for inhibiting protein kinases. Biochim Biophys Acta 2004; 1697 (1-2):233-242.
68. Akalin A, Elmore LW, Forsythe HL, et al. A novel mechanism for chaperonemediated telomerase regulation during prostate cancer progression. Cancer Res 2001; 61:4791-4796.
69. Cardillo MR, Sale P, Di Silverio F. Heat shock protein-90, IL-6 and IL-10 in bladder cancer. Anticancer Res 2000; 20 (6B):4579-4583.
70. Hermisson M, Strik H, Rieger J, et al. Expression and functional activity of heat shock proteins in human glioblastoma multiforme. Neurology 2000; 54:1357-1365.
71. Ito T, Kawabe R, Kurasono Y. Expression of heat shock proteins in squamous cell carcinoma of the tongue: an immunohistochemical study. J Oral Pathol Med 1998; 27:18-22.
72. Nanbu K, Konishi I, Komatsu T, et al. Expression of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Correlation with clinicopathology, sex steroid receptor status, and p53 protein expression. Cancer 1996; 77:330-338.
73. Ogata M, Naito Z, Tanaka S, et al. Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma. J Nippon Med Sch 2000; 67:177-185.
74. Yano M, Naito Z, Tanaka S, Asano G. Expression and roles of heat shock proteins in human breast cancer. Jpn J Cancer Res 1996; 87:908-915.
75. Yano M, Naito Z, Yokoyama M, et al. Expression of hsp90 and cyclin D1 in human breast cancer. Cancer Lett 1999; 137:45-51.
76. Blagosklonny MV, Fojo T, Bhalla KN, et al. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 2001; 15:1537-1543.